Prenetics Global Ltdのファンダメンタルズは比較的非常に健全です。成長の可能性は高いです。バリュエーションは適正価格と評価されています。バイオテクノロジー & 医療研究業界での順位は387中114位です。機関投資家保有率は非常に高いです。過去1か月間に複数のアナリストが買いと評価し、最高目標株価は31.00とされています。中期的には、株価は下降トレンドと予想されます。株式市場でのパフォーマンスはこの1か月で非常に低調でしたが、同社のファンダメンタルズとテクニカルは堅調です。株価は支持線と抵抗線の間で横ばい推移しており、レンジ相場でのスイングトレードに適しています。
Prenetics Global Ltdのスコア
関連情報
業界内順位
114 / 387
全体ランキング
238 / 4565
業種
バイオテクノロジー & 医療研究
サポートラインとレジスタンスライン
会社から関連データがまだ開示されていません。
レーダーチャート
現在
前回値
メディア報道
過去24時間
報道レベル
非常に低い
非常に高い
ポジティブ
Prenetics Global Ltdの注目ポイント
強みリスク
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.